$ACOG

Opaleye Management Inc. purchased $12K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 2,000 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $5.83 on 2026-05-28.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published May 29, 2026, 11:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
low confidence
Mentioned
$ACOG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The disclosure may slightly improve sentiment among traders tracking insider activity, but it does not introduce new company-specific fundamentals (no guidance, trial, deal, or regulatory update).

02

Market read

ACOG saw a reported 10% owner buy, which can be interpreted as mild bullish sentiment but is unlikely to drive a major repricing alone.

03

What to watch

No 10b5-1 plan is cited; however, the filing still doesn’t clarify intent, horizon, or whether the holder has been buying/selling consistently.

Relevance 6/10Novelty 6/10Timing: Filed/visible on SEC EDGAR today; transaction dated 2026-05-28.

Background

The filing is an SEC Form 4 insider transaction: Opaleye Management Inc. (10% owner) reported an open-market purchase of Alpha Cognition shares.

Company-level read

Ticker impact

$ACOGBullishLow confidence
Context

Opaleye Management Inc., a 10% owner, bought 2,000 shares of Alpha Cognition (ACOG) on 2026-05-28 at $5.8320/share via an open-market purchase.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

This is an SEC Form 4 disclosure (timely), but it provides no operational update—only a small open-market purchase by a large holder.

Market effects

No direct sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

Large-holder buying on a small, open-market Form 4 can reflect liquidity/portfolio rebalancing rather than a strong conviction signal.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4; shares purchased by a 10% owner via open-market purchase.

  • Opaleye Management Inc.

    Reported the purchase of 2,000 shares of ACOG at $5.8320/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.